Joseph Jr. Manko Acquires 30,367 Shares of Myomo (NYSEAMERICAN:MYO) Stock

Myomo, Inc. (NYSEAMERICAN:MYO) Director Joseph Jr. Manko purchased 30,367 shares of Myomo stock in a transaction that occurred on Friday, May 15th. The stock was acquired at an average price of $0.89 per share, for a total transaction of $27,026.63. Following the transaction, the director directly owned 2,309,775 shares of the company’s stock, valued at $2,055,699.75. The trade was a 1.33% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.

Myomo Trading Up 4.7%

Shares of MYO opened at $0.88 on Wednesday. The company’s fifty day moving average is $0.77 and its 200 day moving average is $0.84. Myomo, Inc. has a fifty-two week low of $0.61 and a fifty-two week high of $3.45. The stock has a market capitalization of $33.93 million, a PE ratio of -2.44 and a beta of 1.39. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.36 and a current ratio of 2.73.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Dynamic Technology Lab Private Ltd bought a new position in Myomo during the first quarter valued at $75,000. Invesco Ltd. bought a new position in Myomo during the second quarter valued at $37,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Myomo during the second quarter valued at $38,000. Acadian Asset Management LLC bought a new position in Myomo during the first quarter valued at $114,000. Finally, Engineers Gate Manager LP increased its position in Myomo by 62.8% during the second quarter. Engineers Gate Manager LP now owns 30,097 shares of the company’s stock valued at $65,000 after acquiring an additional 11,614 shares during the last quarter. Institutional investors own 44.99% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Craig Hallum restated a “buy” rating on shares of Myomo in a research report on Tuesday, March 10th. Four equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $7.67.

Myomo Company Profile

Myomo, Inc (NYSE American: MYO) is a medical robotics company specializing in developing and commercializing powered orthotic devices designed to restore mobility and function for individuals with upper-limb weakness. The company’s flagship product, the MyoPro®, is an FDA-cleared, wearable robotic orthosis that leverages proprietary sensors and actuators to detect and amplify users’ own muscle signals, enabling patients with conditions such as stroke, spinal cord injury, muscular dystrophy and other neuromuscular disorders to perform daily activities with greater independence.

Myomo markets the MyoPro through a network of licensed orthotic and prosthetic professionals, clinics and hospitals across North America.